Development and characterization of the novel human osteosarcoma cell line COS-33 with sustained activation of the mTOR pathway.

ABSTRACT: Outcomes have not improved for metastatic osteosarcoma for several decades. In part, this failure to develop better therapies stems from a lack of understanding of osteosarcoma biology, given the rarity of the disease and the high genetic heterogeneity at the time of diagnosis. We report here the successful establishment of a new human osteosarcoma cell line, COS-33, from a patient-derived xenograft and demonstrate retention of the biological features of the original tumor. We found high mTOR signaling activity in the cultured cells, which were sensitive to a small molecule inhibitor, rapamycin, a suppressor of the mTOR pathway. Suppressed mTOR signaling after treatment with rapamycin was confirmed by decreased phosphorylation of the S6 ribosomal protein. Increasing concentrations of rapam

SUBMITTER: VanCleave A 

PROVIDER: S-EPMC7343631 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature